Literature DB >> 17707652

Structure, expression and function of HLA-G in renal cell carcinoma.

Barbara Seliger1, Gerald Schlaf.   

Abstract

Tumors have developed different strategies to escape from immune cell recognition which include the downregulation or loss of the classical HLA class I antigens as well as aberrant expression of non-classical HLA antigens like HLA-G. Abnormalities in MHC class surface expression have also been described in renal cell carcinoma (RCC) and represent mechanisms to avoid elimination by immune effector cells. We here review the structure/polymorphism, mRNA and protein expression profile of HLA-G in RCC and corresponding normal kidney epithelium, its mode of regulation and its functional consequences on immune responses. A heterogeneous constitutive HLA-G mRNA and/or protein expression was found in both RCC lesions and RCC cell lines, whereas normal kidney epithelium totally lack HLA-G mRNA and protein expression. In comparison to other tumor entities, the frequency of HLA-G expression is relatively high in RCC. Since HLA-G expression is lost during cultivation of RCC cells, the tumor microenvironment and/or endothelium appear to be involved in the regulation of HLA-G expression in this disease. HLA-G expression could be transcriptionally upregulated in RCC by interferons, IL-10 and gangliosides. Silencing of HLA-G expression in RCC is often associated with methylation of the HLA-G promoter which could be reverted by the treatment with demethylating agents. Functional studies using natural killer cells, lymphokine activated killer cells as well as antigen-specific CD8+ cytotoxic T lymphocytes demonstrated that HLA-G expression prevents lysis of RCC cells by these different immune effector cells. In contrast, HLA-G-negative normal kidney cells as well as HLA-G-negative RCC cells were not recognized by NK and T cells. Thus, HLA-G represents one important immune escape mechanism of human RCC which has an impact on the design of T and NK cell-based immunotherapies in this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17707652     DOI: 10.1016/j.semcancer.2007.07.001

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  14 in total

1.  The Autoimmune Regulator (Aire) transactivates HLA-G gene expression in thymic epithelial cells.

Authors:  Breno Luiz Melo-Lima; Isabelle Poras; Geraldo Aleixo Passos; Edgardo D Carosella; Eduardo Antonio Donadi; Philippe Moreau
Journal:  Immunology       Date:  2019-08-19       Impact factor: 7.397

Review 2.  Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?

Authors:  Laurence Amiot; Soldano Ferrone; Hans Grosse-Wilde; Barbara Seliger
Journal:  Cell Mol Life Sci       Date:  2010-11-10       Impact factor: 9.261

3.  Low expression of human histocompatibility soluble leukocyte antigen-G (HLA-G5) in invasive cervical cancer with and without metastasis, associated with papilloma virus (HPV).

Authors:  Marcia C M Guimarães; Christiane P Soares; Eduardo A Donadi; Sophie F M Derchain; Liliana A L A Andrade; Tarsia G A Silva; Marcela K Hassumi; Renata T Simões; Fabiana A Miranda; Régia C P Lira; Janaina Crispim; Edson G Soares
Journal:  J Histochem Cytochem       Date:  2009-09-28       Impact factor: 2.479

Review 4.  Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.

Authors:  Shernan G Holtan; Douglas J Creedon; Paul Haluska; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

Review 5.  Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association.

Authors:  Eduardo A Donadi; Erick C Castelli; Antonio Arnaiz-Villena; Michel Roger; Diego Rey; Philippe Moreau
Journal:  Cell Mol Life Sci       Date:  2010-11-24       Impact factor: 9.261

6.  Case-control study of HLA-G promoter methylation status, HPV infection and cervical neoplasia in Curitiba, Brazil: a pilot analysis.

Authors:  Anna Gillio-Tos; Maria da Graça Bicalho; Valentina Fiano; Chiara Grasso; Valentina Tarallo; Laura De Marco; Morena Trevisan; Marinabarbaradesousa Xavier; Renata Slowik; Newton S Carvalho; Carlos A Maestri; Hadriano M Lacerda; Daniela Zugna; Lorenzo Richiardi; Franco Merletti
Journal:  BMC Cancer       Date:  2012-12-24       Impact factor: 4.430

Review 7.  Non-classical transcriptional regulation of HLA-G: an update.

Authors:  Philippe Moreau; Sébastien Flajollet; Edgardo D Carosella
Journal:  J Cell Mol Med       Date:  2009-06-05       Impact factor: 5.310

Review 8.  Transcriptional and posttranscriptional regulations of the HLA-G gene.

Authors:  Erick C Castelli; Luciana C Veiga-Castelli; Layale Yaghi; Philippe Moreau; Eduardo A Donadi
Journal:  J Immunol Res       Date:  2014-03-13       Impact factor: 4.818

Review 9.  Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicine.

Authors:  Amanda Mickley; Olga Kovaleva; Julia Kzhyshkowska; Alexei Gratchev
Journal:  EPMA J       Date:  2015-10-20       Impact factor: 6.543

10.  Hypoxia inducible factor-1 mediates the expression of the immune checkpoint HLA-G in glioma cells through hypoxia response element located in exon 2.

Authors:  Layale Yaghi; Isabelle Poras; Renata T Simoes; Eduardo A Donadi; Jörg Tost; Antoine Daunay; Bibiana Sgorla de Almeida; Edgardo D Carosella; Philippe Moreau
Journal:  Oncotarget       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.